Instagram Ern-EyeFacebook Ern-EyeTwitter Ern-EyeLinkedIn Ern-EyeYouTube Ern-EyeHow to use the speech recognition tool?
NCT01756456
REPARO
Evaluation of safety and efficacy of r-hNGF in patients with stage 2 and 3 Neurotrophic Keratitis (REPARO).
Type: Interventional
Status of the trial: Completed
Orphan Drug Recognition: NA
Inclusion
- Opening Date: 2013-05-23
- Closing Date: 2015-03-06
Criteria
Children: No
Adults: Yes
Funder Type: industry
HCP: Principal investigators
- National Reference Center of Keratoconus (CRNK), CHU Toulouse, France
- RÉFÉRET National Hospital of Ophthalmology of Quinze-Vingts, Paris, France
- AOU Careggi - AOU Meyer Consortium, Firenze, Itlay
- University Hospital of Padova, Padova, Italy
- Eye Center, University Hospital Freiburg, Germany
- Moorfields Eye Hospital NHS Foundation Trust
- Central Manchester University Hospitals NHS Foundation Trust, Manchester AcademicHealth Sciences Centre (MAHSC)
HCP: Other investigators
Within ERN-EYE members
Principal investigators
Other investigators
Workgroups
Anterior Segment Rare Eye Diseases (WG4)
This ERN is supported by:
